3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Classical hematology
1
Conditions
Breast Neoplasms
33
Colorectal Neoplasms
12
Neoplasms
11
Pain, Postoperative
10
Lung Neoplasms
9
Brain Neoplasms
8
Stomach Neoplasms
7
Prostatic Neoplasms
7
Pancreatic Neoplasms
7
Carcinoma, Non-Small-Cell Lung
7
Melanoma
6
Leukemia, Myeloid, Acute
5
Ovarian Neoplasms
4
Myoma
4
Lymphoma, Non-Hodgkin
4
Leiomyoma
4
Hemorrhage
4
Head and Neck Neoplasms
4
Glioblastoma
4
Colonic Neoplasms
4
Agnosia
4
Skin Neoplasms
3
Recurrence
3
Rectal Neoplasms
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Neurotoxicity Syndromes
3
Neoplasm Metastasis
3
Nasopharyngeal Carcinoma
3
Myelodysplastic Syndromes
3
Multiple Endocrine Neoplasia Type 1
3
Interventions
Meropenem
7
Vancomycin
6
Filgrastim
5
Ceftazidime
5
pegylated granulocyte colony-stimulating factor
4
Cefepime
4
pegfilgrastim
3
Levofloxacin
3
Ciprofloxacin
3
Amikacin
3
Teicoplanin
2
Piperacillin, Tazobactam Drug Combination
2
Linezolid
2
Interleukin 1 Receptor Antagonist Protein
2
Amoxicillin-Potassium Clavulanate Combination
2
ceftolozane, tazobactam drug combination
1
Vaccination
1
Therapeutics
1
Tazobactam
1
TKN732
1
Sodium Chloride
1
Simvastatin
1
Positron Emission Tomography Computed Tomography
1
Pneumococcal Vaccines
1
Piperacillin
1
Ofloxacin
1
NF protocol
1
N,N'-bis(pyridoxal-5-phosphate)ethylenediamine-N,N'-diacetic acid
1
Micafungin
1
Metronidazole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Febrile Neutropenia
×
Sodium Chloride
×
Clear all
NCT01619423
2018-07-06
PLIANT
Egetis Therapeutics
Phase 1/2
Completed
186 enrolled
12 charts